The CHSY1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population engineered to disrupt the CHSY1 gene in the human Raji B-lymphocyte cell line. This loss-of-function model is generated via targeted gene disruption, resulting in a heterogeneous pool of edited cells that collectively ablate CHSY1 expression. The polyclonal format provides a practical and robust system for studying the functional consequences of CHSY1 deficiency within a Burkitt??s lymphoma background, avoiding the clonal variability inherent in single-cell-derived lines. Researchers can utilize this knockout population to investigate chondroitin sulfate biology without the confounding effects of clonal selection, making it suitable for high-throughput screening and population-level analyses.
The Raji cell line, an EBV-positive Burkitt??s lymphoma model derived from a human B lymphocyte, is widely employed in immunology and oncology research. These cells retain key features of B-cell biology, including robust proliferation, antibody production capacity, and the ability to present antigens. As a lymphoma model, Raji cells are instrumental for studying B-cell malignancies, immune surveillance, and the tumor microenvironment. Their well-characterized genetic landscape and ease of culture make them a preferred host for gene knockout studies, particularly those addressing the roles of glycosaminoglycans in lymphoma pathogenesis, immune evasion, and drug resistance.
CHSY1 encodes a dual glycosyltransferase that catalyzes the elongation of chondroitin sulfate chains, forming the repeating disaccharide backbone of chondroitin sulfate proteoglycans. It functions in concert with CSGALNACT1, CSGALNACT2, CHPF, and CHPF2 to polymerize glycosaminoglycan chains. CHSY1 is transcriptionally regulated by SOX9 and is activated by TGF-beta, BMP, and FGF signaling. Its principal downstream targets include versican, aggrecan, and CD44, all of which depend on chondroitin sulfate modifications for proper function. Disruption of CHSY1 thus severs a critical node in proteoglycan biosynthesis and extracellular signaling.
In the context of Raji B-cells, CHSY1 knockout disrupts the chondroitin sulfate polymerization required for mature proteoglycan synthesis, leading to truncated glycosaminoglycan chains on molecules such as versican and CD44. This molecular lesion impairs cell surface signaling, matrix adhesion, and migratory capacity, potentially altering lymphoma cell behavior and interactions with the tumor microenvironment. Given the role of chondroitin sulfate in modulating growth factor presentation (including TGF-beta family ligands) and integrin-mediated adhesion, loss of CHSY1 may influence pathways relevant to Burkitt??s lymphoma aggressiveness and therapeutic vulnerability. The model thus provides a tool to dissect how glycosaminoglycan defects reshape B-cell lymphoma biology.
This knockout cell population is well-suited for diverse applications. Users can validate CHSY1 disruption via RT-qPCR and Western blot, evaluate proteoglycan changes, and profile cell surface glycans by flow cytometry. Functional assays for adhesion, migration, and invasion, combined with drug sensitivity testing and RNA-seq, can dissect the contribution of chondroitin sulfate to lymphoma cell behavior and therapy response. Key research areas include chondroitin sulfate function in B-cell lymphoma, glycosaminoglycan biosynthesis, cancer cell adhesion and metastasis, and drug resistance. For additional information, contact Ascent Research.
